Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

A French Technology Transfer Office offers a preventive and therapeutic treatment against food allergies

Country of Origin: France
Reference Number: TOFR20180315002
Publication Date: 23 March 2018

Summary

A French Technology Transfer Office (TTO) offers a new treatment against food allergies thanks to the administration of a commercialized drug at a lower dosage. This new technology is useful for the food allergy therapy and prevention market. 
The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a technical cooperation agreement.

Description

A French TTO acting on behalf of major life science research labs in Paris region, has patented the use of interleukin-2 (IL2) at low dosage to prevent and cure food allergy by inducing non-specific tolerance against food allergens. 

Food allergies are an increasing health issue, worldwide. There is no treatment commercially available to treat them. The current standard of care is strict avoidance of the offending allergens and immediate access to rescue medications, such as epinephrine and antihistamines. Indeed, the great majority of allergic patients are treated by symptomatic medication using drugs that exhibit general anti-inflammatory activity and/or reverse bronchoconstriction or vasodilatation. However, symptomatic medication fails to target the mechanisms underlying allergic disease, and often has only short activity.
Specific immunotherapies showed good results for some allergies but these strategies showed rather low efficacy in the case of food allergies and more precisely for peanut or egg allergies. There is therefore a need for an effective long-term treatment and protection against food allergies.

The use of IL-2 at a lower dosage in the case of food allergy showed promising therapeutic results in a mouse model of ovalbumin induced allergy (egg allergy), providing a long-term effectiveness over a 10-month period study.
This treatment also provides a good preventive treatment against peanut allergy and promising results for its therapeutic effect.
The clinical symptoms due to these allergies (pruritis, piloerection, oedema, lethargy or diarrhea) are drastically reduced.

The partner sought could be a company interested in :
- a license agreement (the TTO is able to negotiate directly the intellectual property transactions for specific applications), or
- a technical cooperation agreement to validate the preclinical data and launch clinical trials

Advantages and Innovations

Desensitization (progressive administration of low-doses allergens) for food allergies could be a solution but implies the development of a specific treatment for each allergy.
The development of hypoallergenic food could be also an alternative but it means to launch many R&D efforts to offer this new kind of food.
A drug for treating several types of food allergy could be a very good solution.

The advantages of this new technology are:
-therapeutic treatment
-preventive treatment
-new indication of a marketed molecule at a lower dosage (drug safety has already been validated)
-universal treatment for food allergies

Stage Of Development

Under development/lab tested

Stage Of Development Comment

Stage of development: pre-clinical data are available in order to enter in clinical trials
The proof of concept has been validated in vivo in relevant mice models

Requested partner

The partner sought could be:
-a company involved in the field of allergy interested in developing some more efficient therapeutic solutions or,
-a company developing immunomodulation strategies.
This technology could interest drugs formulation companies or commercializing companies (pharma or biotech).

Technical cooperation agreement: the potential industrial partner should be interested to invest in co-development for another specific food allergy (milk, fish,…).

License agreement: the potential industrial partner should be interested in negotiating a license agreement in order to commercialize a new drug using the patented compound for peanut or egg allergies (after launching clinical trials).

Cooperation offer ist closed for requests